Lorenzo Bertani, Luca Antonioli, Marco Fornili, Vanessa D'Antongiovanni, Linda Ceccarelli, Luca Carmisciano, Laura Benvenuti, Maria Gloria Mumolo, Andrea Bottari, Veronica Pardi, Giovanni Baiano Svizzero, Laura Baglietto, Nicola De Bortoli, Massimo Bellini, Matteo Fornai, Francesco Costa
{"title":"血清细胞因子基线评估可预测克罗恩病患者对乌司替库单抗的临床和内镜反应：一项前瞻性试点研究。","authors":"Lorenzo Bertani, Luca Antonioli, Marco Fornili, Vanessa D'Antongiovanni, Linda Ceccarelli, Luca Carmisciano, Laura Benvenuti, Maria Gloria Mumolo, Andrea Bottari, Veronica Pardi, Giovanni Baiano Svizzero, Laura Baglietto, Nicola De Bortoli, Massimo Bellini, Matteo Fornai, Francesco Costa","doi":"10.1093/ibd/izae133","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>No biomarkers are currently available to predict therapeutic response to ustekinumab (UST) in Crohn's disease (CD). The aim of this prospective study was to identify 1 or more cytokines able to predict mucosal healing in patients with CD treated with UST.</p><p><strong>Methods: </strong>We prospectively enrolled consecutive CD patients treated with UST. At weeks 0 (baseline), 24, and 48, a panel of serum cytokines was measured by a fluorescence assay. At the same time points, fecal calprotectin (FC) was assessed. A colonoscopy was performed at baseline and at week 48, where therapeutic outcome was evaluated in terms of mucosal healing.</p><p><strong>Results: </strong>Out of 44 patients enrolled, 22 (50%) achieved mucosal healing at the end of follow-up. Response was associated with higher interleukin (IL)-23 levels (P < .01). Fecal calprotectin levels decreased over time in responders but did not change in nonresponders (test for the interaction between time and mucosal healing, P < .001).</p><p><strong>Conclusions: </strong>This pilot study showed that IL-23 and FC could be reliable biomarkers in predicting therapeutic outcome to UST therapy in CD. In particular, the correlation between baseline serum levels of IL-23 and mucosal healing at 48 weeks is particularly strong, paving the way for its use to drive therapeutic decisions.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"2449-2456"},"PeriodicalIF":4.5000,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Baseline Assessment of Serum Cytokines Predicts Clinical and Endoscopic Response to Ustekinumab in Patients With Crohn's Disease: A Prospective Pilot Study.\",\"authors\":\"Lorenzo Bertani, Luca Antonioli, Marco Fornili, Vanessa D'Antongiovanni, Linda Ceccarelli, Luca Carmisciano, Laura Benvenuti, Maria Gloria Mumolo, Andrea Bottari, Veronica Pardi, Giovanni Baiano Svizzero, Laura Baglietto, Nicola De Bortoli, Massimo Bellini, Matteo Fornai, Francesco Costa\",\"doi\":\"10.1093/ibd/izae133\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>No biomarkers are currently available to predict therapeutic response to ustekinumab (UST) in Crohn's disease (CD). The aim of this prospective study was to identify 1 or more cytokines able to predict mucosal healing in patients with CD treated with UST.</p><p><strong>Methods: </strong>We prospectively enrolled consecutive CD patients treated with UST. At weeks 0 (baseline), 24, and 48, a panel of serum cytokines was measured by a fluorescence assay. At the same time points, fecal calprotectin (FC) was assessed. A colonoscopy was performed at baseline and at week 48, where therapeutic outcome was evaluated in terms of mucosal healing.</p><p><strong>Results: </strong>Out of 44 patients enrolled, 22 (50%) achieved mucosal healing at the end of follow-up. Response was associated with higher interleukin (IL)-23 levels (P < .01). Fecal calprotectin levels decreased over time in responders but did not change in nonresponders (test for the interaction between time and mucosal healing, P < .001).</p><p><strong>Conclusions: </strong>This pilot study showed that IL-23 and FC could be reliable biomarkers in predicting therapeutic outcome to UST therapy in CD. In particular, the correlation between baseline serum levels of IL-23 and mucosal healing at 48 weeks is particularly strong, paving the way for its use to drive therapeutic decisions.</p>\",\"PeriodicalId\":13623,\"journal\":{\"name\":\"Inflammatory Bowel Diseases\",\"volume\":\" \",\"pages\":\"2449-2456\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2024-12-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Inflammatory Bowel Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/ibd/izae133\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammatory Bowel Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ibd/izae133","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：目前尚无生物标志物可预测克罗恩病（CD）患者对乌司替单抗（UST）的治疗反应。这项前瞻性研究旨在确定一种或多种细胞因子，以预测接受 UST 治疗的 CD 患者的粘膜愈合情况：我们前瞻性地招募了接受 UST 治疗的连续 CD 患者。在第 0 周（基线）、第 24 周和第 48 周，我们采用荧光测定法检测了一系列血清细胞因子。在同一时间点，还对粪便钙蛋白（FC）进行了评估。在基线和第 48 周时进行结肠镜检查，根据粘膜愈合情况评估治疗效果：结果：在 44 名入选患者中，22 人（50%）在随访结束时实现了粘膜愈合。白细胞介素（IL）-23水平升高与疗效有关（P 结论：白细胞介素（IL）-23水平升高与疗效有关：这项试点研究表明，IL-23 和 FC 是预测 CD UST 治疗效果的可靠生物标志物。特别是，IL-23的基线血清水平与48周时的粘膜愈合之间的相关性特别强，这为使用IL-23推动治疗决策铺平了道路。
Baseline Assessment of Serum Cytokines Predicts Clinical and Endoscopic Response to Ustekinumab in Patients With Crohn's Disease: A Prospective Pilot Study.
Background: No biomarkers are currently available to predict therapeutic response to ustekinumab (UST) in Crohn's disease (CD). The aim of this prospective study was to identify 1 or more cytokines able to predict mucosal healing in patients with CD treated with UST.
Methods: We prospectively enrolled consecutive CD patients treated with UST. At weeks 0 (baseline), 24, and 48, a panel of serum cytokines was measured by a fluorescence assay. At the same time points, fecal calprotectin (FC) was assessed. A colonoscopy was performed at baseline and at week 48, where therapeutic outcome was evaluated in terms of mucosal healing.
Results: Out of 44 patients enrolled, 22 (50%) achieved mucosal healing at the end of follow-up. Response was associated with higher interleukin (IL)-23 levels (P < .01). Fecal calprotectin levels decreased over time in responders but did not change in nonresponders (test for the interaction between time and mucosal healing, P < .001).
Conclusions: This pilot study showed that IL-23 and FC could be reliable biomarkers in predicting therapeutic outcome to UST therapy in CD. In particular, the correlation between baseline serum levels of IL-23 and mucosal healing at 48 weeks is particularly strong, paving the way for its use to drive therapeutic decisions.
期刊介绍：
Inflammatory Bowel Diseases® supports the mission of the Crohn''s & Colitis Foundation by bringing the most impactful and cutting edge clinical topics and research findings related to inflammatory bowel diseases to clinicians and researchers working in IBD and related fields. The Journal is committed to publishing on innovative topics that influence the future of clinical care, treatment, and research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
